Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125629 · ClinicalTrials.gov registry record · Phase 2
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT03125629: Completed Phase 2 study, sponsored by Stanford University.
NCT03125629 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 53 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03125629, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cancers.
Primary Outcome
Standardized uptake value max (SUVmax) is a measurement of the maximum radiopharmaceutical uptake value within the region of interest (ROI). SUVmax is calculated as the ratio of activity concentration:injected dose/body weight. The outcome is reported as the mean SUVmax with standard deviation (SD), reported for 8 specific organs or bodily locations.
Interventions
- DRUG F-18 FDG
- DRUG Ga-68-DOTA-TATE
- DEVICE Positron Emission Tomography / Computed Tomography (PET/CT) Scan
- DEVICE Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-05-27 |
| Est. Completion | 2020-02-05 |
| Phase | Phase 2 |
What the finished NCT03125629 record still lists
NCT03125629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 4 interventions - of which F-18 FDG is the first listed.
NCT03125629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03125629 about?
NCT03125629 is a clinical study titled "Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals". This clinical trial studies how well positron emission tomography (PET)/computed tomography (CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of cancer and other types of cance...
What is the current status of trial NCT03125629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2014-05-27. Estimated completion is 2020-02-05.
What interventions are being tested in trial NCT03125629?
The interventions under investigation include: F-18 FDG (DRUG), Ga-68-DOTA-TATE (DRUG), Positron Emission Tomography / Computed Tomography (PET/CT) Scan (DEVICE), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan (DEVICE).
Who is sponsoring clinical trial NCT03125629?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03125629's enrollment target sits among peer trials
53 1171st of 2000 higher than 820 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI